Invesco
CRBP icon

Invesco’s Corbus Pharmaceuticals CRBP Stock Holding History

Invesco’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,784
Closed -$216K – 3780
2024
Q2 		$216K Buy
+4,784
New +$201K ﹤0.01% 3600
2021
Q2 		– Sell
-645
Closed -$38K – 3979
2021
Q1 		$38K Buy
645
+121
+23% +$7.95K ﹤0.01% 3839
2020
Q4 		$20K Buy
+524
New +$19.6K ﹤0.01% 3761

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Invesco's CRBP Position: Q3 2024 in Review

Invesco sold out of Corbus Pharmaceuticals (CRBP) in Q3 2024, closing a stake of 4,784 shares — an estimated $216K sold.

Invesco first reported a position in CRBP in Q4 2020 and held it in 3 quarters. The position peaked at $216K in Q2 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q3 2024.

  • Invesco reported no remaining Corbus Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Invesco sold 4,784 Corbus Pharmaceuticals shares in Q3 2024, an estimated $216K.
  • Invesco first reported a position in Corbus Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Invesco's Corbus Pharmaceuticals position peaked at $216K in Q2 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2024.

Based on Invesco's 13F filing for Q3 2024, filed 12 Nov 2024.